Includes 8 Oral Presentations and Award of Best Clinical Abstract ARTARMON, Australia, Jan. 21, 2020 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical") today announced that data from ...
Evoke is a novel, closed-loop SCS system that instantaneously reads, records, and responds to evoked compound action potentials. The Food and Drug Administration (FDA) has approved the Evoke ® Spinal ...
MINNEAPOLIS, Aug. 4, 2023 /PRNewswire/ -- Saluda Medical, Inc. ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies ...
Saluda Medical Pty. Ltd., of Artarmon, Australia, made waves in 2019, winning the CE mark for its Evoke closed-loop spinal cord stimulation (SCS) system. The good news kept coming following the ...
The Evoke® SCS System is now covered by all major commercial payers and Medicare, providing broad patient access for this important therapy to over 200 million lives. 20 pain societies pledged their ...
Seastar Medical Holding Corp. was granted a third breakthrough device designation by the U.S. FDA for its Selective Cytopheretic device (SCD), a biomimetic... At the 30th Annual Congress of the ...
MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with ...
MINNEAPOLIS, Jan. 8, 2026 /PRNewswire/ -- Saluda Medical, Inc. (ASX:SLD, "Saluda" or the "Company"), a commercial-stage medical device company focused on developing treatments for chronic neurological ...
ARTARMON, Australia, Jan. 21, 2020 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical") today announced that data from multiple studies evaluating the company's Evoke ® ECAP-Controlled, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results